GlassScriptPhysician profile
Hannah C Powers
NPI 1932585668
$5,321.79
in general payments reported to CMS, 2019-2025
33 companies · $1,627 in 2025
The $1,627 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $291 · 2022: $471 · 2023: $1,337 · 2024: $1,596 · 2025: $1,627.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,560.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,559.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $585.96 | 2021-2025 | |
| Boston Scientific Corporation | $507.43 | 2023-2025 | Watchman Access System, Watchman Flx |
| Pfizer INC. | $501.39 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $500.90 | 2021-2025 | Verquvo, Capvaxive |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $362.50 | 2021-2025 | Lifevest |
| Esperion Therapeutics, INC. | $247.67 | 2022-2025 | Nexletol |
| Amgen INC. | $245.00 | 2022-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $226.60 | 2021-2024 | Xarelto |
| Impulse Dynamics (USA) INC. | $225.87 | 2022-2024 | Optimizer, Optimizer |
| Cvrx, INC. | $204.85 | 2023-2025 | Barostim Neo System |
| Bayer Healthcare Pharmaceuticals INC. | $197.23 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $186.70 | 2023-2025 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals LP | $179.80 | 2021-2025 | Brilinta, Wainua, Farxiga |
| Kiniksa Pharmaceuticals International, Plc | $172.96 | 2024 | Arcalyst |
| Scpharmaceuticals INC. | $160.53 | 2024-2025 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $128.48 | 2024-2025 | Jardiance |
| Heartflow, INC. | $95.88 | 2024-2025 | |
| Kowa Pharmaceuticals America, INC. | $82.52 | 2021-2023 | Livalo |
| Kiniksa Pharmaceuticals, LTD. | $68.37 | 2023 | Arcalyst |
| Abbott Laboratories | $55.25 | 2021-2025 | Aveir |
| Novo Nordisk INC | $52.89 | 2025 | Wegovy, Rybelsus, Ozempic |
| Sanofi-Aventis U.S. LLC | $50.09 | 2024 | |
| Daiichi Sankyo INC. | $46.23 | 2023 | Injectafer |
| Medtronic, INC. | $32.61 | 2022-2023 | Linq II |
| Regeneron Healthcare Solutions, INC. | $28.35 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $26.94 | 2024 | |
| Mindray Ds USA, INC. | $25.38 | 2023 | A7 Anesthesia System |
| Amarin Pharma, INC. | $24.05 | 2021-2022 | |
| Itamar Medical INC | $22.82 | 2025 | Watchpatone |
| Intuitive Surgical, INC. | $22.69 | 2024 | |
| Chiesi USA, INC. | $20.70 | 2024 | Juxtapid |
| Kestra Medical Technology Services, INC. | $17.48 | 2022 | |
| Bridgebio Pharma, INC. | $15.67 | 2025 | Attruby |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hannah Powers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.